<?xml version="1.0" encoding="UTF-8"?>
<p id="para2580">A serious effort to address hepatitis infection began in 1991 with a WHO-sponsored neonatal hepatitis B vaccination project in Lombok. In 1992, the Indonesian Red Cross started programmes for safe blood. These efforts—and more recent active harm reduction measures from 2010—were considered to support the decreasing incidence of HBV and HCV.
 <xref rid="bib261" ref-type="bibr">
  <sup>261</sup>
 </xref> In 1997, hepatitis B immunisation for infants was launched as a national programme and upscaled in 1999 by the introduction of birth-dose vaccination.
 <xref rid="bib262" ref-type="bibr">
  <sup>262</sup>
 </xref> A Hepatitis Control Program within the Ministry of Health was launched in 2012.
 <xref rid="bib263" ref-type="bibr">
  <sup>263</sup>
 </xref> The Indonesian Government issued a decree on the National Control of Viral Hepatitis in 2015, supported by a national budget,
 <xref rid="bib263" ref-type="bibr">
  <sup>263</sup>
 </xref> followed by a decree in 2017 for the Triple Elimination of Mother-to-Child Transmission of HIV, Syphilis, and Hepatitis B by integrating HIV, syphilis, and hepatitis B antenatal screening, prevention, and treatment interventions into Mother-and-Child Health Care services.
 <xref rid="bib264" ref-type="bibr">
  <sup>264</sup>
 </xref> A government assistance programme began in 2017 that provides free testing and direct-acting antiviral drugs for 6000 patients with chronic hepatitis C infection who cannot afford diagnosis and treatment.
 <xref rid="bib36" ref-type="bibr">
  <sup>36</sup>
 </xref> Meanwhile, efforts are made to include these drugs in the Essential Medical List to be used through the public health-care insurance system. Sofosbuvir, simeprevir, daclastavir, and one fixed-combination (elbasvir–grazoprevir) drug are the currently registered direct-acting antivirals in Indonesia.
</p>
